ViroCell
ViroCell Biologics manufactures viral vectors and gene-modified cells to enable novel cell and gene therapies (CGTs) to enter clinical trials.
ViroCell Biologics manufactures viral vectors and gene-modified cells to enable novel cell and gene therapies (CGTs) to enter clinical trials.
ViroCell Biologics manufactures viral vectors and gene-modified cells to enable novel cell and gene therapies (CGTs) to enter clinical trials.
Leveraging the team’s 20-year track record of manufacturing more than 100 unique vectors, ViroCell is helping to accelerate the development of crucial, cutting edge therapies so that disease can recede and progress can prevail.
ViroCell is working in partnership with the Royal Free Hospital and Great Ormond Street Hospital.
Website: www.virocell.com
02/06/2023
An experienced team of Private Markets analytics specialists supporting the industry renowned work of Professor Oliver Gottschalg of HEC Paris is delighted to announce the launch of Gottschalg Analytics as an independent second-generation provider of performance intelligence services for the Private Markets.
30/03/2023
Pension Insurance Corporation Group Limited1 ('PICG' or the 'Company'), ultimate parent company of Pension Insurance Corporation plc ('PIC'), the specialist insurer of UK defined benefit pension schemes, today announces its final results for the 12 months to 31 December 2022.
13/03/2023
DCAC announced proposals to form the Advanced Cables Business Combination in the press release issued by the Company on 20th February 2023. The DCAC Board has now decided to expedite the proposals, and DCAC has therefore agreed an exclusive option to acquire the holding company of Advanced Cables, Global InterConnection Group SA (“GIG” or the “Target”). Besides Advanced Cables, GIG is also the holding company of ASC Energy Limited. It is intended that DCAC will be renamed "Global InterConnection Group Limited" on completion of the Business Combination.
11/11/2022
Long Term Assets Limited ("Long Term Assets" or "LTA"), a Guernsey investment company, today announces its intention to admit its shares to trading ("ITF") on the Specialist Fund Segment of the Main Market of the London Stock Exchange. LTA will then launch a 12-month placing programme, aimed in particular at UK pension funds and other long-term savers. Read more.
10/11/2022
Cyro Cyber has been created to address the dynamic and expanding cyber security requirements of Telent’s core markets across critical national infrastructure, telco service providers and other highly regulated sectors.
01/04/2022
Pension Insurance Corporation Group Limited (“PICG” or the “Company”), ultimate parent company of Pension Insurance Corporation plc (“PIC”), the specialist insurer of defined benefit pension schemes, today announces its final results for the 12 months to 31 December 2021.